Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
TL

NASDAQ · TLSI

TriSalus Life Sciences, Inc.

Healthcare · Medical - Devices

$3.48

Down-$0.15 (-4.13%)

Updated Nov 4, 2026, 10:20 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
247.45M
P/E ratio
-4.6
Dividend yield
0.00%
52-week range
$2.20 – $7.95
Volume
142.09K
Avg. volume
137.4K

Price performance · TLSI

TLSI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

TLSI closed at $3.48 after 21 trading sessions, down 18.50% for the selected period.

Last close
$3.48
Period change
-18.50%
Period low
$3.48
Period high
$4.27
Daily close
View OHLC price history
TLSI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$3.68$3.77$3.395$3.48142.09K
Nov 2, 2026$3.73$3.76$3.585$3.63230.91K
Oct 30, 2026$3.77$3.875$3.66$3.70108.59K
Oct 29, 2026$3.98$4.075$3.79$3.86113.86K
Oct 28, 2026$3.76$3.94$3.76$3.9395.73K
Oct 27, 2026$3.66$3.84$3.60$3.80146.86K
Oct 26, 2026$3.62$3.81$3.53$3.62111.79K
Oct 23, 2026$3.60$3.72$3.57$3.5978.4K
Oct 22, 2026$3.64$3.76$3.63$3.6695.07K
Oct 21, 2026$3.68$3.73$3.595$3.6779.06K
Oct 20, 2026$3.57$3.72$3.57$3.66100.86K
Oct 19, 2026$3.63$3.69$3.52$3.53106.27K
Oct 16, 2026$3.83$3.90$3.58$3.63253.52K
Oct 15, 2026$3.94$4.01$3.865$3.90140.25K
Oct 14, 2026$3.91$4.01$3.80$3.90192.83K
Oct 13, 2026$4.12$4.12$3.94$4.00120.15K
Oct 12, 2026$4.10$4.15$3.97$4.1478.53K
Oct 9, 2026$4.09$4.3199$3.93$4.06198.96K
Oct 8, 2026$4.20$4.20$4.02$4.13275.54K
Oct 7, 2026$4.21$4.422$4.0895$4.25185.28K
Oct 6, 2026$4.39$4.51$4.25$4.27153.6K

Latest TLSI news

The latest Smart Investors Daily articles mentioning TLSI.

Stock researchCompany · Overview

TLSI research

Overview

Company profile and research snapshot.

Company profile

TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.50
Implied upside
—
Analysts
—
TLSI recent ratings
DateFirmRatingTarget
Sep 23, 2026HC Wainwright & Co.Buy—
Sep 9, 2026HC Wainwright & Co.Buy—
May 13, 2026Lake StreetBuy—
Mar 9, 2026Canaccord GenuityBuy—
Mar 6, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call

WESTMINSTER, Colo., October 20, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Tuesday, November 10, 2026, at 8:30 AM eastern time to discuss its financial results for the quarter ended September 30, 2026. A press release detail

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By